{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T09:30:22Z","timestamp":1791538222672,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Juvenile Idiopathic Arthritis (JIA) requires complex care that generate elevated costs, which results in a high economic impact for the family. The aim of this systematic review was to collect and cluster the information currently available on healthcare costs associated with JIA after the introduction of biological therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We comprehensively searched in MEDLINE, EMBASE, Web of Science, Scopus, and Cochrane Databases for studies from January 2000 to March 2021. Reviewers working independently and in duplicate appraised the quality and included primary studies that report total, direct and\/or indirect costs related to JIA for at least one year. The costs were converted to United States dollars and an inflationary adjustment was made.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found 18 eligible studies including data from 6,540 patients. Total costs were reported in 10 articles, ranging from $310 USD to $44,832 USD annually. Direct costs were reported in 16 articles ($193 USD to $32,446 USD), showing a proportion of 55 to 98\u2009% of total costs. Those costs were mostly related to medications and medical appointments. Six studies reported indirect costs ($117 USD to $12,385 USD). Four studies reported costs according to JIA category observing the highest in polyarticular JIA. Total and direct costs increased up to three times after biological therapy initiation. A high risk of reporting bias and inconsistency of the methodology used were found.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The costs of JIA are substantial, and the highest are derived from medication and medical appointments. Indirect costs of JIA are underrepresented in costs analysis.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12969-021-00641-y","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T20:55:43Z","timestamp":1633899343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Economic impact of Juvenile Idiopathic Arthritis: a systematic review"],"prefix":"10.1186","volume":"19","author":[{"given":"Fernando","family":"Garc\u00eda-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Gamboa-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol","family":"Jim\u00e9nez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucero","family":"Ochoa-Alderete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria Alejandra","family":"Barrientos-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neri Alejandro","family":"Alvarez-Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Andrea","family":"Luna-Ru\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingris","family":"Pel\u00e1ez-Ballestas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Victoria","family":"Villarreal-Trevi\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Enrique","family":"de la O-Cavazos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7685-3734","authenticated-orcid":false,"given":"Nadina","family":"Rubio-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,9]]},"reference":[{"key":"641_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10198-016-0786-1","volume":"17","author":"A Kuhlmann","year":"2016","unstructured":"Kuhlmann A, Schmidt T, Treskova M, L\u00f3pez-Bastida J, Linertov\u00e1 R, Oliva-Moreno J, et al. Social\/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe. Eur J Health Econ. 2016;17:79\u201387.","journal-title":"Eur J Health Econ"},{"key":"641_CR2","doi-asserted-by":"crossref","unstructured":"Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112-7.","DOI":"10.1016\/j.jbspin.2013.09.003"},{"issue":"1","key":"641_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12969-019-0321-x","volume":"17","author":"MMA Kip","year":"2019","unstructured":"Kip MMA, Currie G, Marshall DA, Grazziotin Lago L, Twilt M, Vastert SJ, et al. Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review. Pediatr Rheumatol Online J. 2019;17(1):20.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"641_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1546-0096-11-24","volume":"11","author":"A Ens","year":"2013","unstructured":"Ens A, Lang B, Ramsey S, Stringer E, Huber AM. The financial burden of juvenile idiopathic arthritis: a Nova Scotia experience. Pediatr Rheumatol. 2013;11(1):6.","journal-title":"Pediatr Rheumatol"},{"issue":"9","key":"641_CR5","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/ard.61.9.818","volume":"61","author":"HM Lapsley","year":"2002","unstructured":"Lapsley HM, March LM, Tribe KL, Cross MJ, Courtenay BG, Brooks PM. Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis. 2002;61(9):818\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"641_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12969-021-00524-2","volume":"17","author":"B Fortuna-Reyna","year":"2021","unstructured":"Fortuna-Reyna B, de Pel\u00e1ez-Ballestas J, Garc\u00eda-Rodr\u00edguez I, Faugier-Fuentes F, Mendieta-Zer\u00f3n E, Villarreal-Trevi\u00f1o S, et al. Psychosocial and economic impact of rheumatic diseases on caregivers of Mexican children. Pediatr Rheumatol Online J. 2021;17(1):30.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"641_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12891-016-1129-1","volume":"17","author":"A Angelis","year":"2016","unstructured":"Angelis A, Kanavos P, L\u00f3pez-Bastida J, Linertov\u00e1 R, Serrano-Aguilar P. Socioeconomic costs and health-related quality of life in juvenile idiopathic arthritis: a cost-of-illness study in the United Kingdom. BMC Musculoskelet Disord. 2016;17(1):1\u20139.","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"641_CR8","first-page":"225","volume":"144","author":"JF Mould-Quevedo","year":"2008","unstructured":"Mould-Quevedo JF. El costo de las principales enfermedades reum\u00e1ticas. Gac M\u00e9d M\u00e9x. 2008;144(3):225\u201331.","journal-title":"Gac M\u00e9d M\u00e9x"},{"key":"641_CR9","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"issue":"1","key":"641_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.18553\/jmcp.2003.9.1.53","volume":"9","author":"JJ Ofman","year":"2003","unstructured":"Ofman JJ, Sullivan SD, Neumann PJ, Chiou C-F, Henning JM, Wade SW, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9(1):53\u201361.","journal-title":"J Manag Care Pharm"},{"key":"641_CR11","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"641_CR12","unstructured":"National Institutes of Health. Study quality assessment tools. Quality assessment tool for observational cohort and cross-sectional studies. [cited 2021 Sep 23]. Available from: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"641_CR13","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [cited 2021 Sep 23]. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"23","key":"641_CR14","first-page":"415","volume":"126","author":"DA Hughes","year":"2018","unstructured":"Hughes DA, Culeddu G, Plumpton CO, Dick AD, Bs MB, Jones AP, et al. Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis. Opthalmology. 2018;126(23):415\u201324.","journal-title":"Opthalmology"},{"key":"641_CR15","doi-asserted-by":"crossref","unstructured":"Khatun M, Datta D, Hazra A, Ghosh P, Selim MB, Mondal R. Economic burden of juvenile idiopathic arthritis in India. Indian Pediatr. 2021;58(1):38\u201340.","DOI":"10.1007\/s13312-021-2094-9"},{"key":"641_CR16","doi-asserted-by":"crossref","unstructured":"Kip MMA, de Roock S, Currie G, Marshall DA, Grazziotin LR, Twilt M, et al. Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system. Expert Rev Pharmacoecon Outcomes Res. 2021;21(5):975-984.","DOI":"10.1080\/14737167.2021.1857241"},{"issue":"7","key":"641_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/ard.2003.008516","volume":"63","author":"K Minden","year":"2004","unstructured":"Minden K, Niewerth M, Listing J, Biedermann T, Sch\u00f6ntube M, Zink A. Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(7):836\u201342.","journal-title":"Ann Rheum Dis"},{"key":"641_CR18","unstructured":"Minden K, Niewerth M, Listing J, M\u00f6bius D, Thon A, Ganser G, et al. The economic burden of juvenile idiopathic arthritis \u2013 results from the German paediatric rheumatologic database. Pediatr Rheumatol. 2009;27(5):863-9."},{"key":"641_CR19","doi-asserted-by":"crossref","unstructured":"Prince FHM, Bekker-grob EW, De, Twilt M, Rossum MAJ, Van, Hoppenreijs EPAH, Cate R, et al. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register. Rheumatology. 2011;(January):1131\u20136.","DOI":"10.1093\/rheumatology\/keq432"},{"issue":"5","key":"641_CR20","first-page":"920","volume":"36","author":"S Shenoi","year":"2018","unstructured":"Shenoi S, Horneff G, Cidon M, Ramanan AV, Kimura Y, Quartier P, et al. The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review. Clin Exp Rheumatol. 2018;36(5):920\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"641_CR21","doi-asserted-by":"crossref","unstructured":"Thakral A, Pinto D, Miller M, Curran ML, Klein-Gitelman M, French DD. Direct healthcare costs associated with oligoarticular juvenile idiopathic arthritis at a single center. Int J Rheumatol. 2020;2020:1\u20135.","DOI":"10.1155\/2020\/5640425"},{"key":"641_CR22","doi-asserted-by":"crossref","unstructured":"Thornton J, Lunt M, Ashcroft DM, Baildam E, Foster H, Davidson J, et al. Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis. Rheumatology. 2008;(April):985\u201390.","DOI":"10.1093\/rheumatology\/ken039"},{"key":"641_CR23","doi-asserted-by":"crossref","unstructured":"Bernatsky S, Duffy C, Malleson P, Feldman DE, St. Pierre Y, Clarke AE. Economic impact of juvenile idiopathic arthritis. Arthritis Rheum. 2007;57(1):44\u20138.","DOI":"10.1002\/art.22463"},{"key":"641_CR24","doi-asserted-by":"crossref","unstructured":"Mars N, Kerola A, Kauppi M, Pirinen M, Elonheimo O, Sokka-Isler T. Patients with rheumatic diseases share similar patterns of healthcare resource utilization. Scand J Rheumatol. 2019;48(4):300\u20137.","DOI":"10.1080\/03009742.2018.1559878"},{"issue":"2","key":"641_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/03009742.2018.1475580","volume":"48","author":"NJ Mars","year":"2019","unstructured":"Mars NJ, Kerola AM, Kauppi MJ, Pirinen M, Elonheimo O, Sokka-Isler T. Healthcare costs and outcomes in adult patients with juvenile idiopathic arthritis: a population-based study. Scand J Rheumatol. 2019;48(2):114\u201320.","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"641_CR26","first-page":"2286","volume":"31","author":"J Haapasaari","year":"2004","unstructured":"Haapasaari J, Kautiainen HJ, Isom\u00e4ki HA, Hakala M. Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2286\u20139.","journal-title":"J Rheumatol"},{"key":"641_CR27","doi-asserted-by":"crossref","unstructured":"Kemal I, Emire Y. Economic impact of juvenile idiopathic arthritis and familial Mediterranean fever. Rheumatol Int. 2012;32(7):1955-62.","DOI":"10.1007\/s00296-011-1894-y"},{"key":"641_CR28","doi-asserted-by":"crossref","unstructured":"Marshall A, Gupta K, Pazirandeh M, Bonafede M, McMorrow D. Treatment patterns and economic outcomes in patients with juvenile idiopathic arthritis. Clin Outcomes Res. 2019;11:361\u201371.","DOI":"10.2147\/CEOR.S197117"},{"key":"641_CR29","unstructured":"Haapasaari J, Kautiainen HJ, Hakala M.\u00a0Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2286."},{"key":"641_CR30","doi-asserted-by":"crossref","unstructured":"El-Matary W, Kuenzig ME, Singh H, Okoli G, Moghareh M, Kumar H, et al. Disease-associated costs in children with inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2020;26(2):206\u201315.","DOI":"10.1093\/ibd\/izz120"},{"issue":"10","key":"641_CR31","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.23512","volume":"70","author":"A Hresko","year":"2018","unstructured":"Hresko A, Lin T-C, Solomon DH. Medical care costs associated with rheumatoid arthritis in the US: a systematic literature review and meta-analysis. Arthritis Care Res. 2018;70(10):1431\u20138.","journal-title":"Arthritis Care Res"},{"key":"641_CR32","doi-asserted-by":"crossref","unstructured":"Soriano E, Catay, Castel del Cid, Narvaez, Velozo, Rosa J, et al. Cost of rheumatoid arthritis in a selected population from Argentina in the prebiologic therapy era. Clin Outcomes Res. 2012;4:219-25.","DOI":"10.2147\/CEOR.S28845"},{"issue":"11","key":"641_CR33","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/acr.21755","volume":"64","author":"AA Kawatkar","year":"2012","unstructured":"Kawatkar AA, Jacobsen SJ, Levy GD, Medhekar SS, Venkatasubramaniam KV, Herrinton LJ. Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. Arthritis Care Res. 2012;64(11):1649\u201356.","journal-title":"Arthritis Care Res"},{"key":"641_CR34","doi-asserted-by":"crossref","unstructured":"Poole CD, Lebmeier M, Ara R, Rafia R, Currie CJ. Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Rheumatology. 2010;49(10):1949\u201356.","DOI":"10.1093\/rheumatology\/keq182"},{"issue":"4","key":"641_CR35","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.clinthera.2009.04.002","volume":"31","author":"DA Ollendorf","year":"2009","unstructured":"Ollendorf DA, Klingman D, Hazard E, Ray S. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther. 2009;31(4):825\u201335.","journal-title":"Clin Ther"},{"issue":"2","key":"641_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1586\/14737167.2015.1001370","volume":"15","author":"KP Malinowski","year":"2015","unstructured":"Malinowski KP, Kawalec P. The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2015;15(2):285\u2013300.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"10","key":"641_CR37","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S2352-4642(19)30188-9","volume":"3","author":"SJW Shoop-Worrall","year":"2019","unstructured":"Shoop-Worrall SJW, Wu Q, Davies R, Hyrich KL, Wedderburn LR. Predicting disease outcomes in juvenile idiopathic arthritis: challenges, evidence, and new directions. Lancet Child Adolesc Health. 2019;3(10):725\u201333.","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"641_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12969-018-0288-z","volume":"16","author":"G Tiller","year":"2018","unstructured":"Tiller G, Buckle J, Allen R, Munro J, Gowdie P, Cox A, et al. Juvenile idiopathic arthritis managed in the new millennium: one year outcomes of an inception cohort of Australian children. Pediatr Rheumatol. 2018;16(1):69.","journal-title":"Pediatr Rheumatol"},{"key":"641_CR39","doi-asserted-by":"crossref","unstructured":"Chhabra A, Robinson C, Houghton K, Cabral DA, Morishita K, Tucker LB, et al. Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience. Rheumatology. 2020;59(12):3727\u201330.","DOI":"10.1093\/rheumatology\/keaa118"},{"issue":"4","key":"641_CR40","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/acr.23709","volume":"71","author":"K Minden","year":"2019","unstructured":"Minden K, Horneff G, Niewerth M, Seipelt E, Aringer M, Aries P, et al. Time of disease-modifying antirheumatic drug start in juvenile idiopathic arthritis and the likelihood of a drug\u2010free remission in young adulthood. Arthritis Care Res. 2019;71(4):471\u201381.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"641_CR41","doi-asserted-by":"publisher","first-page":"128","DOI":"10.14309\/ajg.0000000000000503","volume":"115","author":"LE Targownik","year":"2020","unstructured":"Targownik LE, Kaplan GG, Witt J, Bernstein CN, Singh H, Tennakoon A, et al. Longitudinal trends in the direct costs and health care utilization ascribable to inflammatory bowel disease in the biologic era: results from a Canadian population-based analysis. Am J Gastroenterol. 2020;115(1):128\u201337.","journal-title":"Am J Gastroenterol"},{"key":"641_CR42","doi-asserted-by":"crossref","unstructured":"Wu AC, Fuhlbrigge AL, Robayo MA, Shaker M. Cost-effectiveness of biologics for allergic diseases. J Allergy Clin Immunol Pract. 2021;9(3):1107-1117.e2.","DOI":"10.1016\/j.jaip.2020.10.009"},{"key":"641_CR43","doi-asserted-by":"crossref","unstructured":"Agache I, Song Y, Posso M, Alonso-Coello P, Rocha C, Sol\u00e0 I, et al. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. Allergy Eur J Allergy Clin Immunol. 2020;(July):1\u201314.","DOI":"10.22541\/au.159423110.06430562"},{"issue":"1","key":"641_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12969-020-00481-2","volume":"18","author":"LE Lunt","year":"2020","unstructured":"Lunt LE, Shoop-Worrall S, Smith N, Cleary G, McDonagh J, Smith AD, et al. Validation of novel patient-centred juvenile idiopathic arthritis-specific patient-reported outcome and experience measures (PROMs\/PREMs). Pediatr Rheumatol. 2020;18(1):91.","journal-title":"Pediatr Rheumatol"},{"issue":"1","key":"641_CR45","doi-asserted-by":"publisher","first-page":"e001517","DOI":"10.1136\/rmdopen-2020-001517","volume":"7","author":"E Mosor","year":"2021","unstructured":"Mosor E, Studenic P, Alunno A, Padjen I, Olsder W, Ramiro S, et al. Young people\u2019s perspectives on patient-reported outcome measures in inflammatory arthritis: results of a multicentre European qualitative study from a EULAR task force. RMD Open. 2021;7(1):e001517.","journal-title":"RMD Open"},{"key":"641_CR46","doi-asserted-by":"crossref","unstructured":"McDonald J, Cassedy A, Altaye M, Andringa J, Cooper AM, Drews-Botsch C, et al. Comprehensive assessment of quality of life, functioning and mental health in children with juvenile idiopathic arthritis and non\u2010infectious uveitis. Arthritis Care Res. 2021;10.1002\/acr.24551.","DOI":"10.1002\/acr.24551"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00641-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-021-00641-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00641-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T16:56:29Z","timestamp":1673456189000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00641-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,9]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["641"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00641-y","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,9]]},"assertion":[{"value":"17 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research received approval by the Research Committee of the \u201cDr. Jos\u00e9 E. Gonz\u00e1lez\u201d University Hospital with registration code RVS19-007.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}